Author:
Kelner Michael J.,McMorris Trevor C.,Rojas Rafael J.,Estes Leita A.,Suthipinijtham Pharnuk
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference39 articles.
1. Britten CD, Hilsenbeck SG, Eckhardt SE, Mangold G, MacDonald JR, Von Hoff DD, Weitman S (1999) Enhanced antitumor activity of MGI 114 in combination with irinotecan and 5-fluorouracil in the HT-29 human colon tumor xenograft model. Cancer Res 59:1049–1053
2. Chou T-C (1991) The median-effect principle and the combination index for quantification of synergism and antagonism. In: Chou T-C, Rideout DE (eds) Synergism and antagonism in chemotherapy. Academic Press, New York, pp 61–102
3. Chou T-C, Motzer JR, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of Taxol, Topotecan, and Cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517–1523
4. Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ (2001) Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol 48:413–416
5. Gong J, Vaidyanathan VG, Yu X, Kensler TW, Peterson LA, Sturla SJ (2007) Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent. J Amer Chem Soc 129:2101–2111
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献